Prøve GULL - Gratis
“We Have Streamlined The Whole Process Of Reviewing And Approval”
Bio Spectrum
|October 2017
Indian Council of Medical Research (ICMR) signed an agreement recently with other global agencies to develop and implement policies within the next 12 months that require all trials they fund, co-fund, sponsor or support to be registered in a publicly available registry.
ICMR as a signatory to the statement agreed to monitor compliance with registration requirements and to endorse the development of systems to monitor results reporting. Most of these trials and their results will be accessible via WHO's International Clinical Trials Registry Platform which is a unique global database of clinical trials that compiles data from 17 registries around the world.
Dr Manbeena Chawla of BioSpectrum India spoke to Dr Soumya Swaminathan, Director General, ICMR & Secretary, Department of Health Research (DHR) about the measures taken by ICMR to improve the CROs space in the country.
Excerpts of the interview
What measures ICMR has taken up to boost the clinical trials space in the country?
Denne historien er fra October 2017-utgaven av Bio Spectrum.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Bio Spectrum
Bio Spectrum
Can India's CDMOS Lead the Next Biopharma Wave?
India's Contract, Development, and Manufacturing Organisation (CDMO) sector is projected to grow from $3-3.5 billion today to $22-25 billion by 2035, noted Boston Consulting Group (BCG).
8 mins
March 2026
Bio Spectrum
Telangana turns catalyst for innovation
Telangana is at a pivotal moment in its journey as a global life sciences hub.
6 mins
March 2026
Bio Spectrum
Is AI the New Weapon in the Fight to End TB?
A report released at the India AI Impact Summit 2026, organised by the Government of India, reveals that artificial intelligence (AI) is being successfully deployed at scale across India’s public healthcare system to address the growing burden of tuberculosis (TB).
2 mins
March 2026
Bio Spectrum
ChemWerth on-boards Chandrakanth Reddy as new GSM to increase generic API footprint in India
US-based ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market.
1 min
March 2026
Bio Spectrum
Beyond the Glass Ceiling: Women-Led Companies Shaping India's Health Economy
Over the past decade, women entrepreneurs have gained strong ground in India's healthcare sector, building ventures in diagnostics, FemTech, biotech, and care delivery.
5 mins
March 2026
Bio Spectrum
"There needs to be a collaborative effort between innovators and policymakers to create frameworks that ensure safety without stifling progress"
Started in 2021, Decode Age, one of the pioneers in Longevity Research in India, entered its next phase of growth following its Pre-Series A funding round, led by Granules India.
5 mins
March 2026
Bio Spectrum
Rainbow Children's Medicare appoints Abrarali Dalal as Chief Executive Officer
Rainbow Children's Medicare, a leading provider of paediatrics, perinatal, and women's healthcare services in India, has announced the appointment of Abrarali Dalal as Chief Executive Officer, effective from January 20, 2026.
1 min
March 2026
Bio Spectrum
Haleon ropes in Kedar Lele as President for India Subcontinent
Haleon, a British multinational consumer healthcare company has announced the appointment of Kedar Lele as President for India Subcontinent (ISC), effective January 2026.
1 min
March 2026
Bio Spectrum
Centre revises Startup Recognition Framework to strengthen Startup India Action Plan
The government of India has revamped the Startup Recognition Framework to further strengthen the Startup India Action Plan and take forward the Prime Minister's vision of positioning India as a global innovation powerhouse, manufacturing-led economy and hub for emerging tech.
1 min
March 2026
Bio Spectrum
"In the coming 5 years from now, no Indian CROS will grow or survive without the use of AI"
In January 2026, Ahmedabad-based Veeda Lifesciences announced a strategic leadership transition that marks a new chapter in the company's evolution.
5 mins
March 2026
Translate
Change font size

